Companies · Pharmaceuticals

BMP Sunstone CORP

PLYMOUTH MEETING · Pharmaceuticals

Diligence memoA one-page analyst read on BMP Sunstone CORP — recommendation, valuation, rhythm, risks.
$6.3M
Total raised · real
1
Rounds
Latest step-up
Top 55%
Sector rank · raised
Series A
Latest stage · inferred · Mon Mar 16 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

BMP Sunstone CORP looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.72× the median modeled value of Series A Pharmaceuticals companies in 2007–2009 (18 peers) — value vs value, same stage and era.
  • Within the normal band (72% of peer median) for its niche.
Dormant
  • Last raise 17.3 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

BMP Sunstone CORP is one of 1610 Pharmaceuticals companies tracked from PLYMOUTH MEETING. By capital raised it ranks mid-pack (ahead of 46% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2009-03-16 Raised $6.3M (real) Modeled valuation $197M (est)$6.3M$197MSeries A2009

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.3M · 2009

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$196.7M
Base estimate est.
$7.3M
Conservative case
$1.1B
Upside case
$28.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
17.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
17.3 yr
On record since
2009
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.3M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.2× above median
This company$6.3M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 2.6× above median
This company$196.7M
Sector median$76.1M

Raised more than 46% of sector peers (real $). Modeled value above 68% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #14 of 18.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Sinocom Pharmaceutical, Inc. · Series A Raised $15.0M · modeled $464.6M (est)Vitae Pharmaceuticals, Inc · Series A Raised $15.0M · modeled $464.6M (est)QUATRX PHARMACEUTICALS Co · Series A Raised $14.0M · modeled $434.4M (est)Qrxpharma Ltd · Series A Raised $12.4M · modeled $384.0M (est)Elixir Pharmaceuticals, Inc. · Series A Raised $12.0M · modeled $371.5M (est)Bayhill Therapeutics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Victory Pharma Inc · Series A Raised $10.0M · modeled $309.7M (est)China Biologic Products, Inc. · Series A Raised $9.6M · modeled $295.9M (est)CHINA BAICAOTANG MEDICINE Ltd · Series A Raised $15.3M · modeled $276.9M (est)Apr, Llc · Series A Raised $8.8M · modeled $271.8M (est)Hs Pharmaceuticals LLC · Series A Raised $8.6M · modeled $264.9M (est)Kun Run Biotechnology, Inc. · Series A Raised $8.0M · modeled $247.8M (est)BMP Sunstone CORP (this company) Raised $6.3M · modeled $196.7M (est)BMP Sunstone CORP
CompanyStageRaised · realValue · estvs peer med.
Sinocom Pharmaceutical, Inc.Series A$15.0M$464.6M1.69×
Vitae Pharmaceuticals, IncSeries A$15.0M$464.6M1.69×
QUATRX PHARMACEUTICALS CoSeries A$14.0M$434.4M1.58×
Qrxpharma LtdSeries A$12.4M$384.0M1.40×
Elixir Pharmaceuticals, Inc.Series A$12.0M$371.5M1.35×
Bayhill Therapeutics, Inc.Series A$10.0M$309.7M1.13×
Victory Pharma IncSeries A$10.0M$309.7M1.13×
China Biologic Products, Inc.Series A$9.6M$295.9M1.08×
CHINA BAICAOTANG MEDICINE LtdSeries A$15.3M$276.9M1.01×
Apr, LlcSeries A$8.8M$271.8M0.99×
Hs Pharmaceuticals LLCSeries A$8.6M$264.9M0.97×
Kun Run Biotechnology, Inc.Series A$8.0M$247.8M0.90×
BMP Sunstone CORP this companySeries A$6.3M$196.7M0.72×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.3M2009-03-16$28.9M$196.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.3M2009-03-16
    • First recorded raise — entered as Series A.
Intelligence
Modeled next raise
$10.2M
Modeled next size est.range $6.6M$16.3M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Martyn D. Greenacre2 other2009-03
Fred M. Powell1 other2009-03
George Bickerstaff1 other2009-03
Zhijun Tong1 other2009-03
Albert Yeung2009-03
David (Xiaoying) Gao2009-03
Frank J Hollendoner2009-03
Jack M Ferraro2009-03
John W Stakes2009-03
Yanping Zhao2009-03
Zhiqiang Han2009-03
Registry & provenance

BMP Sunstone CORP is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1281696
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Irisys, LlcPharmaceuticalsSeries A$6.3M$195.1Msame sector · same stage
Skyline Vet Pharma, Inc.PharmaceuticalsSeries A$6.4M$155.2Msame sector · same stage
Innocutis Holdings, LLCPharmaceuticalsSeries A$6.5M$201.3Msame sector · same stage
NephroGenex, Inc.PharmaceuticalsSeries A$6.5M$170.3Msame sector · same stage
Novalere FP, Inc.PharmaceuticalsSeries A$6.5M$201.3Msame sector · same stage
Spinifex Pharmaceuticals IncPharmaceuticalsSeries A$6.2M$191.0Msame sector · same stage
Pocket Naloxone Corp.PharmaceuticalsSeries A$6.2M$139.2Msame sector · same stage
Zafrens Inc.PharmaceuticalsSeries A$6.2M$97.5Msame sector · same stage
Frequently asked
How much funding has BMP Sunstone CORP raised?
BMP Sunstone CORP has raised approximately $6.3M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is BMP Sunstone CORP's estimated valuation?
Provath's modeled valuation for BMP Sunstone CORP is approximately $196.7M (modeled range $7.3M–$1.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is BMP Sunstone CORP at?
BMP Sunstone CORP's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Mar 16.
What does BMP Sunstone CORP do and where is it based?
BMP Sunstone CORP operates in the Pharmaceuticals sector, based in PLYMOUTH MEETING.
Explore related

See where BMP Sunstone CORP sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at BMP Sunstone CORP, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.